At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
MEDI5884 +1 moredrug
Likely dose
MEDI5884 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease
In Brief
A Phase 2 clinical trial evaluating MEDI5884 and Placebo for Stable Coronary Heart Disease. Completed, enrolled 133 participants across 23 sites.
Detailed Summary
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Coronary Heart Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartDec 2017
Primary CompletionNov 2018
TodayJul 2026
First PostedNov 24, 2017
Enrollment StartDec 13, 2017
Primary CompletionNov 9, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.6 years ago
Interventions
MEDI5884drug
Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
Placebodrug
Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.